Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
Mean weight change was -13.6% with oral semaglutide versus -2.2% placebo; multiple categorical weight-loss thresholds also favored semaglutide.
What this study tells us
Participants were assigned to comparison groups by chance, usually with placebo and/or blinding to reduce bias. This is a strong design for testing cause and effect, but the population, duration and endpoints still limit what can be concluded.
Adults with obesity or overweight plus at least one weight-related complication, without diabetes
n=307
Mean weight change was -13.6% with oral semaglutide versus -2.2% placebo; multiple categorical weight-loss thresholds also favored semaglutide.
Formulation/dose-specific obesity trial; do not transfer results to all oral semaglutide products or strengths.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
Mean weight change was -13.6% with oral semaglutide versus -2.2% placebo; multiple categorical weight-loss thresholds also favored semaglutide.